New data from a Phase IIIb study shows Kcentra (Prothrombin Complex Concentrate), from CSL Behring, was superior to plasma, the...
The FDA on 29 April 2013 has approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K...
The FDA has given approval for an expanded indication of Kcentra (prothrombin complex concentrate), from CSL Behring, for use in...
The ideal dosing strategy of 4-factor prothrombin complex concentrate (4FPCC) after warfarin-induced intracranial haemorrhage (WICH) is unknown. Discover more in this publication digest.
Combined with intravenous vitamin K, 4F-PCC is an important first-line agent for patients requiring VKA reversal for major bleeding complications or during invasive surgery.
Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex concentrates (PCCs).
This study examined evidence for non-vitamin K oral anticoagulants, demonstrating that they are at least as effective as older vitamin K antagonists.
Review the latest digest 'Initiation of a fixed‐dose four‐factor prothrombin complex concentrate protocol'.
This study compared data from two phase IIIb randomised controlled trials to assess the relative risk of volume overload occurring as a result of plasma versus 4F-PCC administration.
Background: Plasma is commonly used for vitamin K antagonist (VKA) reversal, but observational studies suggest that it is associated with transfusion-related adverse reactions (e.g., volume overload). However, this issue has not previously been addressed in a randomized controlled trial (RCT).